江苏艾迪药业集团股份有限公司 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688488 证券简称：艾迪药业 公告编号：2025-043 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届监事会第五次 会议通知于 2025 年 8 月 11 日送达全体监事，会议于 2025 年 8 月 14 日在公司会 议室以现场结合通讯表决方式召开。本次会议由公司监事会主席庞秋晨先生召集 并主持，应到监事 3 人，实到监事 3 人。本次会议的召集和召开程序符合《中华 人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 与会监事就如下议案进行了审议，并表决通过以下事项： （一）审议通过《关于调整 2025 年股票期权激励计划相关事项的议案》 监事会认为：鉴于 2025 年股票期权激励计划首次授予的 2 名激励对象因离 职不再符合激励条件，根据《上市公司股权激励管理办法》《公司 2025 年股票期 权激励计划（草案）》及其摘要 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届董事会第五次 会议通知于 2025 年 8 月 11 日以书面或电子邮件方式送达全体董事，会议于 2025 年 8 月 14 日在公司会议室以现场结合通讯表决方式召开。本次会议由董事长傅 和亮先生主持，应到董事 7 名，实到董事 7 名。本次会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定。 二、董事会会议审议情况 与会董事就如下议案进行了审议，并表决通过以下事项： （一）审议通过《关于调整 2025 年股票期权激励计划相关事项的议案》 证券代码：688488 证券简称：艾迪药业 公告编号：2025-042 江苏艾迪药业集团股份有限公司 第三届董事会第五次会议决议公告 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《艾迪药业关于向 2025 年股票期权激励计划激励对象首次授予股票期权的公告》 （公告编号：2025-045）。本议案已经公司 ...

2024年1至12月份，艾迪药业的营业收入构成为：药品制造占比71.59%，生物医药原辅料占比27.07%， 医疗器械占比0.8%，其他业务占比0.54%。 （文章来源：每日经济新闻） 艾迪药业（SH 688488，收盘价：16.8元）8月14日晚间发布公告称，公司第三届第五次董事会会议于 2025年8月14日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于调整2025年股票期权激 励计划相关事项的议案》等文件。 ...

格隆汇8月14日丨艾迪药业(688488.SH)公布，公司于2025年8月14日召开第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于调整2025年股票期权激励计划相关事项的议 ...

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

Group 1 - Zhejiang Dingli achieved a net profit of 1.051 billion yuan in the first half of 2025, a year-on-year increase of 27.49% [1] - The company reported an operating income of 4.336 billion yuan, representing a year-on-year growth of 12.35% [1] - Basic earnings per share were 2.08 yuan [1] Group 2 - Dexin Technology announced that its shareholder plans to reduce its stake by no more than 1%, equating to 2.3351 million shares [1] - The company specializes in the research, design, manufacturing, and sales of lithium battery cutting molds and precision components [1] Group 3 - Fangda Group signed new orders worth 970 million yuan in the second quarter of 2025 [1] - The total amount of signed but uncompleted contracts reached 4.916 billion yuan by the end of the second quarter [1] Group 4 - Warner Pharmaceutical's shareholder plans to reduce its stake by no more than 1.3 million shares, which is approximately 0.9899% of the total share capital [3] - The company focuses on the research, production, and sales of chemical raw materials and traditional Chinese medicine [3] Group 5 - Zijin Mining's vice president plans to reduce his holdings by no more than 250,300 shares [4] - The company is engaged in the exploration and development of mineral resources, including gold, copper, and lithium [4] Group 6 - Shenkong Co. received government subsidies totaling 14.9 million yuan [6] - The company specializes in the research, production, and sales of large-diameter silicon materials and semiconductor products [6] Group 7 - Jincai Hulin's shareholder plans to reduce its stake by no more than 2.5%, which amounts to 19.4798 million shares [1] - The company is involved in heat treatment equipment manufacturing and related services [1] Group 8 - New Media Co. plans to reduce its stake by no more than 6.8434 million shares, approximately 2.99% of the total share capital [1] - The company focuses on IPTV, internet audio-visual services, and content copyright [1] Group 9 - Aidi Pharmaceutical received a drug registration certificate for its product in Zanzibar, allowing for commercial sales [8] - The product is a new drug developed for the treatment of HIV-1 infection [8] Group 10 - Changlan Technology plans to reduce its stake by no more than 1%, equating to 1.9311 million shares [10] - The company specializes in the research, production, and sales of power cable accessories [10] Group 11 - Qiaofeng Intelligent announced that two shareholders plan to reduce their holdings by no more than 2.14% of the total share capital [12] - The company focuses on the research, production, and sales of CNC machine tools [12] Group 12 - Junxin Co. signed a tripartite preliminary agreement to build a solid waste disposal power facility valued at approximately 280 million USD in Almaty [13] - The company specializes in waste incineration power generation and related environmental services [13] Group 13 - Qinglong Pipe Industry signed a strategic cooperation framework agreement with Tian Shan High-tech [14] - The company is involved in the research, production, and sales of high-quality water supply pipes [14] Group 14 - Defang Nano's shareholder plans to reduce its stake by no more than 1%, equating to 2.7954 million shares [1] - The company specializes in the research, production, and sales of lithium-ion battery materials [1] Group 15 - ST Lutong's specific shareholder plans to reduce its stake by up to 3%, including 2 million shares through centralized bidding and 4 million shares through block trading [1] - The company focuses on cable television network equipment and smart control systems [1] Group 16 - Tongzhou Electronics reported a net profit of 203 million yuan in the first half of 2025, a significant turnaround from a loss of 36.08 million yuan in the previous year [17] - The company achieved an operating income of approximately 540 million yuan, representing a year-on-year growth of 606.52% [17] Group 17 - Rebecca reported a net profit of 9.3759 million yuan in the first half of 2025, a year-on-year increase of 15.31% [18] - The company achieved total operating revenue of approximately 598 million yuan, reflecting a year-on-year growth of 4.20% [18] Group 18 - Ruixin Technology's shareholders plan to reduce their holdings by no more than 4.9493 million shares, which is up to 3% of the total share capital [20] - The company specializes in the research, production, and sales of precision aluminum alloy components [20]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-040 江苏艾迪药业集团股份有限公司 关于艾诺米替片获得桑给巴尔药品注册证书的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于近日收到桑给巴尔 （非洲坦桑尼亚联合共和国的组成部分）食品和药品管理局（ZANZIBAR FOOD AND DRUG AGENCY）于 2025 年 7 月 25 日核准签发的艾诺米替片《药品注册 证书》。现将相关情况公告如下： 一、药品注册的基本情况 药品商品名：Aitribond（桑给巴尔当地药品注册名） 规格：艾诺韦林 150mg，拉米夫定 300mg，富马酸替诺福韦二吡呋酯 300mg 药品批准文号：ZNZ76, AR27 JIA 药品注册证书有效期限至：2030 年 7 月 24 日 上市许可持有人：江苏艾迪药业股份有限公司 药品生产企业：江苏艾迪药业股份有限公司 二、药品其他情况 艾诺米替片系公司开发的具有自主知识产权的三联单片复方抗 HIV-1 感染 化学 ...

江苏艾迪药业集团股份有限公司（以下简称"公司"）于近日收到桑给巴尔 （非洲坦桑尼亚联合共和国的组成部分）食品和药品管理局（ZANZIBAR FOOD AND DRUG AGENCY）于 2025 年 7 月 25 日核准签发的艾诺米替片《药品注册 证书》。现将相关情况公告如下： 一、药品注册的基本情况 药品商品名：Aitribond（桑给巴尔当地药品注册名） 证券代码：688488 证券简称：艾迪药业 公告编号：2025-040 江苏艾迪药业集团股份有限公司 关于艾诺米替片获得桑给巴尔药品注册证书的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 规格：艾诺韦林 150mg，拉米夫定 300mg，富马酸替诺福韦二吡呋酯 300mg 药品批准文号：ZNZ76, AR27 JIA 药品注册证书有效期限至：2030 年 7 月 24 日 上市许可持有人：江苏艾迪药业股份有限公司 药品生产企业：江苏艾迪药业股份有限公司 二、药品其他情况 艾诺米替片系公司开发的具有自主知识产权的三联单片复方抗 HIV-1 感染 化学 ...